MTOS Technology is actively seeking strategic partnerships for technology transfer
MTOS-III is a wide-spectrum anti-tumor drug that has demonstrated high complete response rate and high survival rate in advanced-stage patients.
✔ Wide-spectrum anti-tumor efficacy (squamous cancer, lymphatic system tumors, prostate cancer, reproductive system tumors, multiple and recurrent hyperplasia)
✔ Significantly reduces toxic side effects of chemotherapy and radiotherapy (vomiting, anemia, hair loss)
✔ Safe and suitable for long-term use by tumor patients
✔ Marked efficacy
Animal tests confirmed a significant inhibitory effect on transplanted tumor growth, with a positive dose-response relationship.
Many tumor patients have used MTOS-III continuously for more than 5-8 years, proving its reliability and safety in anti-tumor applications.
Registered as a functional food for immune modulation and tumor suppression to obtain research funding.